Solid Tumor Testing Market

The Solid Tumor Testing Market is expanding as cancer diagnosis increasingly shifts toward molecularly informed, targeted, and personalized approaches. Solid tumors include abnormal tissue masses that may be benign or malignant, with major cancer categories such as breast, lung, colorectal, prostate, liver, ovarian, brain, thyroid, melanoma, and endometrial cancers generating substantial demand for accurate diagnostic testing. As cancer incidence increases worldwide, healthcare providers are placing greater emphasis on identifying tumor characteristics, genetic alterations, and biomarkers that can support diagnosis and treatment selection. According to Maximize Market Research, the global Solid Tumor Testing Market was valued at approximately USD 40.73 billion in 2023 and is projected to grow at a CAGR of 7.85% from 2024 to 2030, reaching nearly USD 69.13 billion by 2030.

The development of precision oncology is one of the most important factors reshaping the solid tumor testing industry. Traditional cancer diagnosis largely focused on identifying the presence, location, and stage of a tumor, whereas modern testing increasingly examines the molecular characteristics that distinguish one tumor from another. This shift has increased demand for technologies capable of detecting mutations, gene alterations, biomarkers, and other molecular signatures. Next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other molecular techniques are therefore becoming increasingly important across oncology workflows. Recent research continues to demonstrate the value of comprehensive genomic profiling for identifying actionable alterations and supporting treatment decisions in advanced solid tumors.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 @https://www.maximizemarketresearch.com/request-sample/167421/ 

Key Market Segmentation

By Testing Type

Based on testing type, the Solid Tumor Testing Market is segmented into non-conventional testing and conventional testing. Non-conventional testing includes fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS). According to Maximize Market Research, the non-conventional testing segment dominated the market in 2023 and is expected to maintain its leading position during the forecast period. The segment is supported by growing adoption of genetic testing, increasing development of molecular diagnostic products, rising awareness of genetic testing, and continued identification of new cancer biomarkers.

Within this category, next-generation sequencing held the largest revenue share in 2023 and is expected to record the highest growth rate during the forecast period. NGS enables multiple genes to be analyzed simultaneously, providing a broader molecular profile than conventional single-gene approaches. This capability is particularly valuable when tumors contain several potentially actionable alterations. By reducing the need for sequential gene-by-gene testing, NGS can improve testing efficiency while conserving valuable clinical samples.

The increasing use of NGS in clinical oncology is also connected to the expansion of targeted therapies and companion diagnostics. As more treatments depend on the identification of specific molecular biomarkers, genomic testing becomes an important component of therapy selection. Current oncology research emphasizes comprehensive genomic profiling as a means of identifying mutations and other alterations that may influence targeted or immune-based treatment decisions.

By Application

The market is segmented by application into prostate, breast, colorectal, endometrial, lung, melanoma, brain, thyroid, liver, ovarian, and other cancers. Breast, lung, colorectal, and prostate cancers represent particularly important testing applications because of their prevalence and the growing availability of molecularly targeted treatment options. As the number of targeted therapies expands, tumor testing is becoming increasingly important for determining whether patients possess biomarkers associated with specific treatments.

Lung cancer testing is expected to remain an important area of market development because advanced non-small-cell lung cancer increasingly requires comprehensive biomarker assessment. Modern diagnostic workflows may incorporate IHC, FISH, NGS, and other molecular methods to identify actionable alterations and support treatment planning.

The growing understanding of tumor heterogeneity is also increasing the importance of comprehensive testing. Tumors can contain different cellular populations with distinct genetic characteristics, and these differences can contribute to treatment resistance and disease progression. Research published in 2026 highlights tumor heterogeneity and clonal evolution as major factors influencing therapeutic response, reinforcing the need for increasingly sophisticated molecular characterization.

By End User

Based on end user, the Solid Tumor Testing Market is divided into hospitals, pharmaceutical and biotechnology companies, and contract research organizations (CROs). Hospitals represent an important end-user group because they conduct diagnostic testing as part of cancer diagnosis, staging, treatment selection, and patient monitoring.

Pharmaceutical and biotechnology companies use solid tumor testing extensively during drug development and clinical trials. Biomarker testing can assist in patient selection, evaluation of treatment response, and development of companion diagnostics. CROs also contribute to this ecosystem by providing specialized testing and laboratory services to pharmaceutical companies and research institutions.

Growth Drivers

One of the primary growth drivers is the increasing prevalence of cancer worldwide. Breast, lung, colorectal, prostate, liver, ovarian, and other solid tumors continue to create a substantial diagnostic burden. The aging global population is another important factor because the risk of many cancers increases with age. Maximize Market Research identifies the expanding geriatric population and rising prevalence of multiple tumor types as important factors supporting market expansion.

The increasing number of private diagnostic centers is another factor supporting demand. Growing pressure on public healthcare systems and increasing demand for diagnostic imaging and laboratory services are encouraging the development of private diagnostic infrastructure. Maximize Market Research highlights the establishment of FUJIFILM's NURA cancer screening center in Bengaluru as an example of investment in cancer screening infrastructure.

Increasing healthcare expenditure and technological investment are also supporting market development. Governments, healthcare organizations, diagnostic laboratories, and private companies are investing in modern infrastructure, molecular diagnostics, laboratory automation, and genomic technologies. Such investments improve access to sophisticated testing and create opportunities for diagnostic technology providers.

Another major driver is the growing adoption of precision medicine. Targeted cancer therapies increasingly depend on identifying specific molecular characteristics within tumors. Consequently, diagnostic testing is moving from simply confirming cancer to providing clinically actionable information that can help guide therapy. Broader genomic profiling is attracting particular attention because it can identify alterations that may be missed by narrow, tumor-specific panels. A 2026 prospective Canadian study reported that broader NGS profiling identified previously undetected druggable mutations in a substantial proportion of patients with advanced solid tumors, demonstrating the potential clinical value of comprehensive testing.

Liquid Biopsy and Molecular Testing Create New Opportunities

Although tissue testing remains an important foundation of solid tumor diagnostics, liquid biopsy and circulating tumor DNA (ctDNA) are creating new opportunities. Blood-based molecular testing can provide a less invasive method for monitoring cancer-related genomic changes and may be particularly valuable when tissue is limited or repeated sampling is difficult.

Current market research indicates that tissue continues to account for a larger share of solid tumor testing, while liquid biopsy is growing rapidly as clinicians explore its use for serial monitoring, treatment-response assessment, resistance detection, and minimal residual disease testing.

This development is expanding the role of testing beyond initial diagnosis. Molecular testing is increasingly being explored across the cancer-care pathway, including treatment selection, monitoring, recurrence assessment, and detection of residual disease.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 @https://www.maximizemarketresearch.com/request-sample/167421/ 

Recent Developments

Recent developments demonstrate the industry's movement toward high-sensitivity NGS, comprehensive genomic profiling, and molecular residual disease testing. In September 2026, India's MedGenome launched OncoTrack MRD, a personalized NGS-based tumor-informed molecular residual disease test designed to detect residual cancer through tumor tissue and blood samples. The test is intended for several solid tumors, including breast, lung, colorectal, and ovarian cancers.

Another important development is the expansion of collaborations aimed at making advanced genomic testing more accessible. Illumina and Labcorp expanded their precision-oncology partnership, focusing on distributed NGS-based in-vitro diagnostic tests for comprehensive genomic profiling and whole-genome sequencing. The approach is intended to allow hospitals and community health systems to perform more advanced testing locally, potentially reducing turnaround times and improving access to actionable biomarker information.

The competitive landscape is also being influenced by growing interest in precision oncology. NeoGenomics presented research at the 2026 ASCO Annual Meeting covering minimal residual disease, precision oncology, and real-world evidence across solid tumors and hematologic malignancies, highlighting the industry's continued focus on expanding molecular testing applications.

Competitive Landscape

The Solid Tumor Testing Market is characterized by moderate competition, with global diagnostic companies, molecular testing specialists, genomics technology providers, reference laboratories, and precision oncology firms competing across tissue-based testing, next-generation sequencing (NGS), liquid biopsy, companion diagnostics, and minimal residual disease (MRD) testing. According to recent industry analysis, NGS accounted for more than half of solid tumor testing revenue in 2025, while tissue testing remained the leading sample type. At the same time, liquid biopsy is emerging as one of the fastest-growing areas because of its ability to support minimally invasive genomic profiling and longitudinal cancer monitoring.

Solid Tumor Testing Market, Key Players are

1. Abbott Laboratories
2. Agilent Technologies
3. 20/20 Gene Systems Inc.
4. Thermo Fisher Scientific, Inc.
5. Avant Diagnostics, Inc.
6. Advanced Cell Diagnostics, Inc.
7. Agena Bioscience, Inc.
8. Bio-Rad Laboratories, Inc.
9. Johnson & Johnson`
10. Biocare Medical, LLC.
11. ARUP Laboratories
12. Caris Life Sciences.
13. F. Hoffmann-La Roche Ltd
14. Genomic Testing Cooperative
15. Guardant Health

For full access to the comprehensive strategic report, visit:https://www.maximizemarketresearch.com/market-report/solid-tumor-testing-market/167421/ 

Regional Outlook

North America held the largest share of the global Solid Tumor Testing Market in 2023, accounting for approximately 48% of the market, according to Maximize Market Research. The region benefits from advanced healthcare infrastructure, high cancer incidence, strong adoption of modern diagnostic technologies, established molecular diagnostic companies, and significant research funding. The United States represents the largest market within North America.

Asia Pacific, meanwhile, is expected to register the highest growth rate and gain a larger share of global revenue toward the end of the forecast period. Rising cancer incidence, aging populations, improving healthcare infrastructure, increasing healthcare expenditure, and greater adoption of genetic testing are creating significant opportunities throughout the region. India, China, Japan, South Korea, and other developing healthcare markets are expected to contribute to this expansion.

Market Outlook

The Solid Tumor Testing Market is transitioning toward a more comprehensive and personalized diagnostic model in which molecular information plays an increasingly important role in cancer management. The combination of rising cancer prevalence, increasing investment in healthcare infrastructure, expanding precision-medicine applications, and technological improvements in NGS, PCR, IHC, FISH, and liquid biopsy is expected to sustain market growth.

The market is projected to increase from USD 40.73 billion in 2023 to nearly USD 69.13 billion by 2030, representing a 7.85% CAGR from 2024 to 2030. As genomic testing becomes more integrated into routine oncology, future opportunities are likely to emerge around comprehensive genomic profiling, companion diagnostics, liquid biopsy, MRD monitoring, AI-assisted interpretation, and decentralized testing. These developments could make solid tumor testing increasingly central to earlier diagnosis, treatment selection, disease monitoring, and personalized cancer care.

About maximize Market Research

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Contact maximize Market Research

3rd Floor, Navale IT Park, Phase 2
Pune Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
+91 96071 95908, +91 9607365656